The Lynx Group

Colon Cancer

There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting.
Read Article

The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting.
Read Article

Chicago, IL—The global International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study suggests that some patients with surgically resected stage III colon cancer can safely and effectively receive only 3 months of chemotherapy instead of the standard 6 months. The data were particularly convincing for patients with low-risk, surgically resected stage III colon cancer. These data set a new standard for the treatment of patients with stage III colon cancer, according to expert opinion presented at the 2017 ASCO annual meeting.
Read Article

Left- vs Right-Sided Colon Cancers

Some molecularly targeted agents are proving to be less effective, not more so, when administered earlier in the disease course. Researchers say this is counterintuitive, because advanced disease is associated with treatment refractoriness, and cancer agents will typically perform better in the adjuvant treatment setting than in the metastatic treatment setting.
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: